Literature DB >> 11099169

Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction.

P Porela1, K Pulkki, L M Voipio-Pulkki, K Pettersson, V Leppänen, T J Nevalainen.   

Abstract

OBJECTIVES: Atherosclerotic lesions result from inflammatory-proliferative responses of the endothelium and smooth muscle of the arterial wall. Poor prognosis of acute myocardial infarction (AMI) patients has been associated with elevated levels of acute phase proteins including C-reactive protein. We investigated the significance of circulating phospholipase A2 in the long-term prognosis of suspected AMI patients.
METHODS: The concentration of phospholipase A2 was measured by an immunoassay in sera of 100 suspected AMI patients. Admission phospholipase A2 95 % fractile outliers were excluded to eliminate the effect of acute infectious diseases. The total and atherosclerotic mortalities were followed for a 4-year period.
RESULTS: The most powerful prognostic limit for both admission (p = 0.02, RR = 2.6 and 95% CI = 1.2 to 5.6) and maximal (p = 0.06, RR = 2.4 and 95% CI = 0.96 to 5.9) phospholipase A2 groups was > or =8 microg/l. The admission phospholipase A2 level had an independent prognostic significance for atherosclerotic mortality (p = 0.04, RR = 2.4 and CI = 1.02 to 5.8) in multivariate analysis with CK-MB and age.
CONCLUSIONS: The elevated serum phospholipase A2 level at admission is an independent predictor of long-term atherosclerotic mortality in patients with suspected AMI. The prognostic significance of phospholipase A2 weakens during hospitalisation concomitant to the onset of the acute inflammatory response to myocardial injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099169     DOI: 10.1007/s003950070041

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  4 in total

1.  Secretory phospholipase A2 in patients with coronary artery disease.

Authors:  Luciana Moreira Lima; Maria das Graças Carvalho; Cirilo Pereira da Fonseca Neto; José Carlos Faria Garcia; Marinez Oliveira Sousa
Journal:  J Thromb Thrombolysis       Date:  2009-05-17       Impact factor: 2.300

2.  Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension.

Authors:  Katrin Wenzel; Hannelore Haase; Gerd Wallukat; Wolfgang Derer; Sabine Bartel; Volker Homuth; Florian Herse; Norbert Hubner; Herbert Schulz; Marion Janczikowski; Carsten Lindschau; Christoph Schroeder; Stefan Verlohren; Ingo Morano; Dominik N Muller; Friedrich C Luft; Rainer Dietz; Ralf Dechend; Peter Karczewski
Journal:  PLoS One       Date:  2008-11-17       Impact factor: 3.240

3.  A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.

Authors:  Jose O Leite; Ushma Vaishnav; Michael Puglisi; Heather Fraser; Joaquim Trias; Maria Luz Fernandez
Journal:  BMC Cardiovasc Disord       Date:  2009-02-17       Impact factor: 2.298

4.  Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval.

Authors:  Robert Roberts
Journal:  JACC Basic Transl Sci       Date:  2018-11-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.